JP6329957B2 - 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法 - Google Patents

心不全において血圧を制御するためおよび呼吸困難を低減させるための方法 Download PDF

Info

Publication number
JP6329957B2
JP6329957B2 JP2015539879A JP2015539879A JP6329957B2 JP 6329957 B2 JP6329957 B2 JP 6329957B2 JP 2015539879 A JP2015539879 A JP 2015539879A JP 2015539879 A JP2015539879 A JP 2015539879A JP 6329957 B2 JP6329957 B2 JP 6329957B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
blood pressure
clevidipine
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015539879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535258A (ja
JP2015535258A5 (OSRAM
Inventor
エドワード シー． ジュニア スピンドラー，
エドワード シー． ジュニア スピンドラー，
ロレッタ エム． イトリ，
ロレッタ エム． イトリ，
グレゴリー チャールズ ウィリアムズ，
グレゴリー チャールズ ウィリアムズ，
ミン−イ フー，
ミン−イ フー，
Original Assignee
キエージィ ファーマチェウティチ エス．ペー．アー．
キエージィ ファーマチェウティチ エス．ペー．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キエージィ ファーマチェウティチ エス．ペー．アー．, キエージィ ファーマチェウティチ エス．ペー．アー． filed Critical キエージィ ファーマチェウティチ エス．ペー．アー．
Publication of JP2015535258A publication Critical patent/JP2015535258A/ja
Publication of JP2015535258A5 publication Critical patent/JP2015535258A5/ja
Application granted granted Critical
Publication of JP6329957B2 publication Critical patent/JP6329957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015539879A 2012-10-26 2013-10-26 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法 Active JP6329957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
US61/719,127 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018014665A Division JP2018065875A (ja) 2012-10-26 2018-01-31 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法

Publications (3)

Publication Number Publication Date
JP2015535258A JP2015535258A (ja) 2015-12-10
JP2015535258A5 JP2015535258A5 (OSRAM) 2016-12-08
JP6329957B2 true JP6329957B2 (ja) 2018-05-23

Family

ID=50545374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015539879A Active JP6329957B2 (ja) 2012-10-26 2013-10-26 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法
JP2018014665A Withdrawn JP2018065875A (ja) 2012-10-26 2018-01-31 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018014665A Withdrawn JP2018065875A (ja) 2012-10-26 2018-01-31 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法

Country Status (18)

Country Link
US (1) US10881645B2 (OSRAM)
EP (1) EP2925128B1 (OSRAM)
JP (2) JP6329957B2 (OSRAM)
KR (1) KR102299073B1 (OSRAM)
CN (2) CN110840890A (OSRAM)
AU (1) AU2013334081B2 (OSRAM)
BR (1) BR112015009291B1 (OSRAM)
CA (1) CA2889584C (OSRAM)
EA (1) EA030354B1 (OSRAM)
ES (1) ES2671639T3 (OSRAM)
IL (1) IL238462A0 (OSRAM)
MX (1) MX359768B (OSRAM)
NZ (1) NZ708511A (OSRAM)
PL (1) PL2925128T3 (OSRAM)
TR (1) TR201807636T4 (OSRAM)
UA (1) UA117571C2 (OSRAM)
WO (1) WO2014066870A1 (OSRAM)
ZA (1) ZA201503741B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456617A (zh) 2014-05-19 2017-02-22 医药公司 氯维地平纳米颗粒及其药物组合物
KR20210136048A (ko) * 2019-03-05 2021-11-16 윈드트리 세라퓨틱스, 인크. 급성 심부전 (ahf)의 치료를 위한 이스타록심-함유 정맥내 제형
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
HRP20200136T1 (hr) 2008-08-01 2020-08-21 Chiesi Farmaceutici S.P.A. Farmaceutski pripravci i metode za njihovu stabilizaciju
NZ591205A (en) 2008-08-01 2012-11-30 Medicines Co Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
ES2773040T3 (es) * 2009-11-11 2020-07-09 Chiesi Farm Spa Métodos de tratamiento o prevención de trombosis de stent
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
BR112013008601B1 (pt) * 2010-10-12 2020-03-31 Chiesi Farmaceutici S.P.A. Formulações de emulsão de clevidipina contendo agentes antimicrobianos
JP2014509654A (ja) 2011-04-01 2014-04-21 ザ メディシンズ カンパニー 脳卒中損傷の低減に使用するための短時間作用型ジヒドロピリジン（クレビジピン）

Also Published As

Publication number Publication date
AU2013334081B2 (en) 2017-05-18
KR102299073B1 (ko) 2021-09-09
AU2013334081A1 (en) 2015-06-11
EA030354B1 (ru) 2018-07-31
IL238462A0 (en) 2015-06-30
PL2925128T3 (pl) 2018-10-31
BR112015009291A2 (pt) 2017-07-04
CN104968199A (zh) 2015-10-07
EP2925128B1 (en) 2018-04-11
CA2889584C (en) 2018-08-14
MX2015005341A (es) 2016-05-24
KR20150104084A (ko) 2015-09-14
ZA201503741B (en) 2022-09-28
EA201590825A1 (ru) 2015-09-30
MX359768B (es) 2018-10-10
EP2925128A4 (en) 2016-06-08
ES2671639T3 (es) 2018-06-07
CA2889584A1 (en) 2014-05-01
CN110840890A (zh) 2020-02-28
US20140121247A1 (en) 2014-05-01
TR201807636T4 (tr) 2018-06-21
JP2015535258A (ja) 2015-12-10
EP2925128A1 (en) 2015-10-07
NZ708511A (en) 2018-11-30
UA117571C2 (uk) 2018-08-27
BR112015009291B1 (pt) 2021-03-16
US10881645B2 (en) 2021-01-05
WO2014066870A1 (en) 2014-05-01
JP2018065875A (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
EP3607962B1 (en) Angiotensin ii alone or in combination for the treatment of hypotension
JP2018065875A (ja) 心不全において血圧を制御するためおよび呼吸困難を低減させるための方法
JP2023507626A (ja) 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
EP2878310B1 (en) Sprayable aqueous composition comprising glyceryl trinitrate
BR112013020377B1 (pt) Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
US20180140579A1 (en) Sacubitril and valsartan for treating metabolic disease
JP6629850B2 (ja) 汎用心停止液（変種）
Jang et al. Ivabradine-induced torsade de pointes in patients with heart failure reduced ejection fraction
WO2007112986A1 (en) Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment
Harbalıoğlu et al. Conscious sedation with the combination of midazolam and fentanyl is effective and safe for cryoablation of paroxysmal atrial fibrillation
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
Sato et al. Acute Heart Failure in an Almost-Centenarian Patient With Symptomatic Severe Aortic Stenosis Treated With Ivabradine
Watanabe et al. Effects of a bolus injection of adenosine triphosphate on atrioventricular conduction and hemodynamics in patients undergoing coronary artery bypass grafting
Mousavi Vasopressin and septic shock

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180423

R150 Certificate of patent or registration of utility model

Ref document number: 6329957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250